Treatment with denosumab reduces secondary fracture risk in women with postmenopausal osteoporosis

Abstract

Denosumab reduced the risk of fragility fractures to a similar degree in all risk subgroups examined, including those with prior fragility fractures. Identifying and treating high-risk individuals could help to close the current care gap in secondary fracture prevention.